Rapport Therapeutics (RAPP) had its "buy" rating reaffirmed by BTIG Research. They now have a $53.00 price target on the stock.
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics (RAPP) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Rapport Therapeutics (RAPP) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $66.00 price target on the stock.
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting